---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000015"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:38:07.756247+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Supernus FY 2024 rev $661.8M; Qelbree +72%; ONAPGO approved; SPN-820 Phase 2b fails

## Summary
- Full year 2024 revenue $661.8M (+9% YoY); Qelbree net sales $241.3M (+72%) and GOCOVRI $130.8M (+9%).
- Full year 2024 operating earnings $81.7M vs loss of $(5.3)M in 2023; adjusted operating earnings $183.7M (+47%).
- ONAPGO (apomorphine) FDA approved for advanced Parkinson's; launch planned in Q2 2025.
- SPN-820 Phase 2b in treatment-resistant depression failed primary and secondary endpoints; program future under review.
- FY 2025 guidance: total revenues $600-630M; adjusted operating earnings $105-130M, down from $183.7M in 2024.

## SEC filing metadata
- accession: 0001356576-25-000015
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000015/0001356576-25-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000015/supn-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000015
- JSON: https://secwatch.observer/filing/0001356576-25-000015.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.